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Expression Profiles of miRNA Subsets Distinguish
Human Colorectal Carcinoma and Normal
Colonic Mucosa
Daniel F. Pellatt, MStat1, John R. Stevens, PhD2, Roger K. Wolff, PhD1, Lila E. Mullany, MS1, Jennifer S. Herrick, MS1,
Wade Samowitz, MD3 and Martha L. Slattery, PhD1

OBJECTIVES: MicroRNAs (miRNAs) are small, non-protein-coding RNA molecules that are commonly dysregulated in colorectal
tumors. The objective of this study was to identify smaller subsets of highly predictive miRNAs.
METHODS: Data come from population-based studies of colorectal cancer conducted in Utah and the Kaiser Permanente Medical
Care Program. Tissue samples were available for 1,953 individuals, of which 1,894 had carcinoma tissue and 1,599 had normal
mucosa available for statistical analysis. Agilent Human miRNA Microarray V.19.0 was used to generate miRNA expression profiles;
validation of expression levels was carried out using quantitative PCR. We used random forest analysis and verified findings with
logistic modeling in separate data sets. Important microRNAs are identified and bioinformatics tools are used to identify target
genes and related biological pathways.
RESULTS: We identified 16 miRNAs for colon and 17 miRNAs for rectal carcinoma that appear to differentiate between carcinoma
and normal mucosa; of these, 12 were important for both colon and rectal cancer, hsa-miR-663b, hsa-miR-4539, hsa-miR-17-5p,
hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-4506, hsa-miR-92a-3p, hsa-miR-93-5p, hsa-miR-145-5p, hsa-miR-3651, hsa-miR-378a-3p,
and hsa-miR-378i. Estimated misclassification rates were low at 4.83% and 2.5% among colon and rectal observations,
respectively. Among independent observations, logistic modeling reinforced the importance of these miRNAs, finding the primary
principal components of their variation statistically significant (Po0.001 among both colon and rectal observations) and again
producing low misclassification rates. Repeating our analysis without those miRNAs initially identified as important identified
other important miRNAs; however, misclassification rates increased and distinctions between remaining miRNAs in terms of
classification importance were reduced.
CONCLUSIONS: Our data support the hypothesis that while many miRNAs are dysregulated between carcinoma and normal
mucosa, smaller subsets of these miRNAs are useful and informative in discriminating between these tissues.
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INTRODUCTION
MicroRNA (miRNA or miR) are noncoding RNA molecules that
alter gene activity through both the translation reduction and
the decay of mRNA.1 They regulate key cellular processes
including division and differentiation,2 and altered miRNA
expression has been associated with several diseases
including cancer.3 Dysregulated miRNAs associated with
cancer, including colorectal cancer (CRC) specifically, have
been discussed as potential diagnostic tools4,5 and have
generated treatment ideas.6 Previous studies7–9 have identified several miRNAs with differential expression between
carcinoma and non-tumor tissue among individuals with CRC.
Many of these studies had relatively small sample sizes and
identified and focused on modest lists of differentially
expressed miRNAs. Our previous analysis10 with a comparatively large sample size indicated that over 86% of miRNAs
expressed in 480% of the population were differentially
expressed between carcinoma tissue and normal mucosa. As
more researchers use miRNA arrays that analyze thousands
1

of miRNAs rather than targeted miRNAs, identification of
key miRNAs in the carcinogenic process becomes more
challenging. Given the extent of dysregulated miRNAs in
CRC, it is desirable to identify important subsets of miRNAs
that distinguish these tumors from non-tumor tissue.
Here, we focus on distinctions between the miRNA
expression profiles of carcinoma tissue and those of adjacent
normal mucosa in individuals with CRC. Our aim is to identify
smaller groups of miRNAs with expression profiles that are
highly predictive of carcinoma vs. normal tissue. We use
random forest analysis to identify important miRNAs for
classifying tissue as either carcinoma or normal colonic
tissue. Random forests are competitive classifiers in a variety
of scenarios11,12 and have been proffered as microarray
analysis tools because of their ability to classify using many
input variables compared with the number of observations
while simultaneously providing a useful, cross-validationbased, measure of input variable importance, the out-of-bag
(OOB) error rate.13–15 Our analysis centers around tissue
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Table 1 Samples after pair selection

Primary data set

Secondary data set
Tissue

Tissue

Normal mucosa

Carcinoma

Total

Colon
Male
Female
Total

220
193
413

304
276
580

524
469
993

Rectal
Male
Female
Total

126
93
219

191
150
341

317
243
560

collected from 1,953 individuals with CRC and considers colon
and rectal carcinomas separately. Independent verification
was performed using logistic modeling. For additional insight
into the cellular processes associated with our findings,
bioinformatics tools were used to identify target genes and
related biological pathways associated with specific miRNAs
identified.
METHODS
Study participants. Study participants came from two
population-based case–control studies that included all incident
colon and rectal cancers verified through tumor registries and
between 30 and 79 years of age who resided along the
Wasatch Front in Utah or were members of the Kaiser
Permanente Medical Care Program (KPMCP) in Northern
California as described previously.16,17 Cases were obtained via
a rapid-reporting system; for those cases who did not participate
in the interview portion of the study, deidentified tissue was
obtained via the tumor registry along with tumor characteristics.
Thus, this study includes tissue obtained from 97% of all Utah
cases diagnosed and for 85% of all Kaiser Permanente Medical
Care Program study participants.18 The study was approved by
the University of Utah Institutional Review Board Protocol
numbers IRB_00002335 and IRB_00055877. All study participants provided informed consent.
miRNA processing. After extracting RNA from formalin-fixed,
paraffin-embedded tissue, the Agilent Human miRNA Microarray V.19.0 (Agilent Technologies, Santa Clara, CA) was used
to obtain miRNA expression results for 2,006 unique human
miRNAs.10 Samples that failed initial quality control parameters
established by Agilent that included tests for excessive
background fluorescence, excessive variation among probe
sequence replicates on the array, and measures of the total
gene signal on the array to assess low signal were repeated a
second time. After quality control, there were 1,953 individuals
contributing carcinoma and/or normal mucosa tissue observations among whom 1,894 individuals contributed carcinoma
tissue and 1,599 contributed normal mucosa. Normal mucosa
was taken from the same site adjacent to the index carcinoma.
To minimize differences that could be attributed to the array,
amount of RNA, location on array, or other factors that could
Clinical and Translational Gastroenterology

Normal mucosa

Carcinoma

Total

Male
Female
Total

47
43
90

62
48
110

109
91
200

Male
Female
Total

48
42
90

68
42
110

116
84
200

erroneously influence expression, total gene signal was
normalized by multiplying expression values of each sample
by a scaling factor (median of the 75th percentiles of all the
samples divided by the individual 75th percentile of each
sample), stratified by carcinoma site. We refer to miRNAs
using standard nomenclature used in the miRBase
database.19
Statistical methods. After quality control, observations consisted of 1,193 individuals with colon tissue (carcinoma, normal
mucosa, or both) and 760 with rectal tissue; the colon
observations were considered separately from the rectal
observations. Within these groups, we focused on miRNAs
that were expressed in most individuals, dropping any with zero
measured expression in more than 10% of individuals. This
amounted to considering expression values for 522 miRNAs
among colon observations and 545 miRNAs among rectal
observations for analysis. For the colon study, paired samples
of both carcinoma and normal mucosa tissues were available
for 955 individuals, whereas only one tissue type was available
for 238 individuals. Among the rectal study, these numbers
were 585 and 175, respectively. As our data contained both
paired and non-paired observations and because the models
used are not designed for paired observations, for each
individual with both carcinoma and normal mucosa tissue,
one of these tissue types was randomly kept for model fitting,
whereas the other was withheld for subsequent validation.
Within both the colon and rectal observations, 200 individuals
were randomly selected and set aside to form independent
secondary data sets. Table 1 contains a summary of the nonwithheld observations in the primary and secondary colon and
rectal data sets; a similar table for the withheld pairs is available
in the online Supplementary Table S1 online.
All statistical analysis was performed in R.20 To identify
miRNAs of particular importance in distinguishing normal
mucosa from carcinoma tissue, random forests were fit to the
primary colon and rectal data sets using the R package
“randomForest”.21,22 These models were fit to classify tissue
type, i.e., normal mucosa vs. carcinoma tissue, using miRNA
expression values, sex, and age category as explanatory
variables. Age categories were ⩽ 50, 51–60, 61–70, and 71 or
more years of age at diagnosis. Proximal vs. distal subsite also
was included as an explanatory variable in the random forest
modeling associated with the colon data set. Classification
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error rates and the rankings of variable importance scores did
not meaningfully change when adjusting various model
parameters beyond the default settings of the “randomForest”
package. Aside from setting the number of trees equal to
10,000, the default settings were used. K-means clustering
with k = 2 was applied to the resulting importance scores
associated with the explanatory variables; this was performed
on importance scores resulting from the colon and rectal
models separately. Those explanatory variables that clustered
toward the greatest mean importance measure, all of which
were miRNAs, were selected as being of particular
importance. Supplementary 1 (S1 Text) provides additional
information on the Random Forest procedure used.
Random forests lack some of the parametric structure and
related statistical tests associated with more traditional
modeling techniques. To verify our findings, we fit logistic
models to the secondary colon and rectal data sets (N = 200 in
each). Normal mucosa vs. carcinoma tissue was the outcome
modeled and only the miRNAs identified in the respective
primary data sets as important were considered for modeling.
For each model, rather than including all miRNAs designated
as important as explanatory variables, dimension was
reduced via principal component analysis (PCA) performed
separately for both the secondary colon and rectal data sets
on the mean centered and sample standard deviation scaled
miRNA expressions. The first five principal component scores
were considered as potential explanatory variables for
inclusion in the logistic models. The Akaike information
criterion (AIC) was used to select which components were
included in the final models. The logistic models yielded
P-values associated with the coefficients attached to the
included principal components (alternative hypothesis: coefficient is non-zero). The logistic models were considered further
as classification models. Tissue was classified according to
which type the model estimated to be of greater probability;
leave-one-out cross-validation was used to measure the
associated classification accuracy of the logistic models.
To further assess the accuracy of the random forest and
logistic models, we considered the withheld pairs. Among the
primary and secondary data sets for both colon and rectal
tissue, the models fit to the non-withheld pairs were used to
predict the tissue types of the withheld observations and
misclassification rates were observed. In the secondary data
sets where logistic models were applied, the PCA loadings
computed from the non-withheld secondary data sets were
used to compute PCA scores for the withheld observations so
that no further model fitting was applied to the withheld
observations.
Bioinformatics analysis. To determine target genes
and related biological pathways associated with the
identified miRNAs that classified tissue type, miRNA targets
were generated using DIANA-TarBase V.7.0 (http://diana.
imis.athena-innovation.gr/DianaTools/index.php?r = tarbase/
index),23 a repository of validated miRNA targets. Target
genes were then used as input to the Database for
Annotation, Visualization, and Integrated Discovery (DAVID)
V.6.724,25 (Enriched Gene Ontology (GO))26 terms for
biological processes were then pulled using DAVID’s
Functional Annotation Tool. Biological process terms were

selected as significant using the criterion false discovery rate
o0.05. DAVID uses the Kyoto Encyclopedia of Genes and
Genomes (KEGG).27
Quantitative PCR for validation of Agilent platform
expression measurements. We compared expression
measurements from the Agilent platform with quantitative
PCR (qPCR) measurements to validate data characteristics
across platforms for several miRNAs identified as important.
One hundred and eighty samples, representing 45 normal
mucosa/carcinoma pairs from individuals with colon tumors
and 45 paired samples from individuals with rectal tumors,
were selected for qPCR measurement. cDNA was generated
for 11 specific miRNAs using 10 ng of total RNA in a multiplex
reaction using the TaqMan MicroRNA Reverse Transcription
Kit (Life Technologies, Carlsbad, CA) and TaqMan assayspecific primers (all assays were purchased from Life
Technologies, Carlsbad, CA). A multiplexed 12-cycle preamplification step was performed according to the manufacturer’s recommendation. The preamplified material was then
diluted 1:16 and individual TaqMan assays were performed
using 40 cycles and collecting real-time data on an ABI
7900HT. Data were evaluated using Life Technologies Quant
Studio Flex 12K software (Thermo Fisher Scientific, Waltham,
MA) to determine the number of cycles required for each
sample to cross a common threshold. Ten of these miRNAs
selected for comparison were identified as important among
colon observations, eight of which also were identified as
important among rectal observations. One miRNA, miR-1183, not identified as important in the random forest
analysis was selected for inclusion to serve as a housekeeping gene to control for individual-specific variation. This
specific miRNA was not differentially expressed between
carcinoma and normal mucosa in our data and had high
levels of expression in both tissues in almost all samples.
Expression measurements were normalized using the 2 DC T
method.28,29 To evaluate similarity between the measurements of the two platforms, Agilent expression measurements were contrasted with qPCR expression measurements
among the individuals with colon tumors separately from
those with rectal tumors. For each group, among individuals
for whom both qPCR and Agilent expressions were available
(N = 45), each miRNA identified as important for which qPCR
data was available was considered individually. For each
such miRNA, correlation between Agilent and qPCR expressions was computed among both carcinoma and normal
mucosa samples. Agilent platform fold changes between
carcinoma tissue and normal colonic mucosa also were
compared with fold change measurements from qPCR.
RESULTS
The primary colon and rectal data sets consisted of 52.8% and
56.6% men, respectively, whereas 54.5% and 58.0% of
individuals among the secondary colon and rectal data sets
were men. Of the individuals in the primary colon data set,
50.5% had proximal tumors, whereas 49.5% had distal tumors
and the same percentages were observed among the
secondary colon data set. Considering age at diagnosis,
among individuals in the primary colon data set 9.3% were
Clinical and Translational Gastroenterology
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Figure 1 Greatest importance scores. Green indicates those microRNAs (miRNAs) selected as most important via k-means clustering. 1Mean decrease in tree accuracy
from permutation.

50 years of age or less, 19.6% were between 51 and 60 years,
36.5% were between 61 and 70 years, and 34.6% were 71
years or older; in the secondary colon data set, these
percentages were 11.0%, 12.5%, 39.5%, and 37.0%, respectively. Among individuals in the primary rectal data set, 16.8%
were 50 years of age or less, 22.3% were between 51 and 60
years, 33.8% were between 61 and 70 years, and 27.1% were
71 years or older; these percentages among individuals in the
secondary rectal data set were 16.5%, 22%, 38%, and 23.5%,
respectively.
The random forest models’ importance measurements
paired with k-means analysis (k = 2) identified 16 miRNAs as
most important in discriminating between carcinoma and
normal mucosa for colon cancer; 17 miRNAs were identified
for rectal cancer. Of these miRNAs, 12, hsa-miR-663b,
hsa-miR-4539, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-21-5p,
hsa-miR-4506, hsa-miR-92a-3p, hsa-miR-93-5p, hsa-miR-1455p, hsa-miR-3651, hsa-miR-378a-3p, and hsa-miR-378i, were
identified as important discriminators for both colon and rectal
cancer. We identified hsa-miR-663a, hsa-miR4538, hsa-miR-215,
and hsa-miR-192-5p uniquely in association with colon cancer;
hsa-miR-4323, hsa-miR-150-5p, hsa-miR-4749-3p, hsa-miR-4243p, and hsa-miR-6073 were identified uniquely in association with
rectal cancer. Figure 1 displays the 25 miRNAs with the highest
variable importance scores in both the colon and rectal data sets.
Green text indicates those grouped by k-means clustering as most
important, whereas red text indicates membership in the cluster of
miRNAs with lower importance scores, not all of which are shown.
Sex, age category, and colonic site (i.e., proximal vs. distal colon)
Clinical and Translational Gastroenterology

received variable importance scores among the closest to zero; as
such, the random forest analysis does not provide evidence of
their interaction with the identified miRNAs in terms of classifying
tissue type. Summary information regarding expression values
from the Agilent platform for miRNAs among the clusters of the
greatest mean importance in the colon and rectal data sets are
presented in Table 2.
The OOB error (misclassification) estimate for the random
forest model fit to the primary colon data set was o5% as was
the misclassification rate among the associated paired
observations withheld from the random forest modeling.
Among the primary rectal data set, the estimated error rates
were lower, with an OOB error estimate of 2.50% associated
with the random forest model fit to the primary data set and an
error rate of 3.51% among the pairs withheld from modeling.
Figure 2 illustrates some findings of the random forest models.
It contrasts the expression values of the top three miRNAs, as
determined by importance score rank, against one another
among individuals in the primary colon and rectal data sets
and is color-coded by tissue type.
In the secondary colon data set, the logistic model included
the first three principal components as explanatory variables.
These accounted for 76.41% of the sample variance among
the important miRNAs. For each of these components, the
P-value associated with the model coefficient was o0.001.
The estimated misclassification rate was 6.50% among the
secondary colon observations and 5.10% among the associated pairs withheld from modeling. Considering the secondary rectal data set, the first, third, and four principal
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Table 2 Important miRNA summary statistics

Mean-adjusted counts
miRNA
Colon data set
Hsa-miR-663b
Hsa-miR-4539
Hsa-miR-17-5p
Hsa-miR-20a-5p
Hsa-miR-663a
Hsa-miR-4538
Hsa-miR-21-5p
Hsa-miR-215
Hsa-miR-4506
Hsa-miR-92a-3p
Hsa-miR-93-5p
Hsa-miR-192-5p
Hsa-miR-145-5p
Hsa-miR-3651
Hsa-miR-378a-3p
Hsa-miR-378i
—

Mean-adjusted counts
a

Normal
mucosa

Carcinoma
tissue

Fold change

34.40
83.22
15.07
16.32
276.96
188.66
145.44
66.77
6.62
39.52
13.39
128.10
210.80
23.57
152.31
75.85
—

68.54
53.67
49.57
57.34
416.95
138.38
389.67
39.18
10.06
99.46
34.34
81.90
125.59
52.27
113.77
57.65
—

1.99
0.64
3.29
3.51
1.51
0.73
2.68
0.59
1.52
2.52
2.56
0.64
0.60
2.22
0.75
0.76
—

miRNA
Rectal data set
Hsa-miR-663b
Hsa-miR-17-5p
Hsa-miR-4323
Hsa-miR-20a-5p
Hsa-miR-378a-3p
Hsa-miR-93-5p
Hsa-miR-4539
Hsa-miR-378i
Hsa-miR-21-5p
Hsa-miR-92a-3p
Hsa-miR-145-5p
Hsa-miR-150-5p
Hsa-miR-3651
Hsa-miR-4749-3p
Hsa-miR-4506
Hsa-miR-424-3p
Hsa-miR-6073

Normal
mucosa

Carcinoma
tissue

Fold change

30.79
14.18
14.39
15.07
152.32
13.18
67.90
75.13
127.02
44.28
270.28
38.50
27.47
14.90
5.42
23.45
7.14

61.96
53.07
8.51
60.65
113.25
35.72
44.73
57.02
381.56
115.80
131.80
12.87
59.73
8.83
8.88
36.87
4.43

2.01
3.74
0.59
4.02
0.74
2.71
0.66
0.76
3.00
2.61
0.49
0.33
2.17
0.59
1.64
1.57
0.62

miRNA, microRNA.
a
Calculated as mean normal mucosa/mean carcinoma.

components were included in the logistic model. These
accounted for 59.88% of the sample variance among
important rectal miRNAs. The P-values corresponding to the
coefficients associated with these components within the fitted
logistic model were all o0.05. The misclassification rate
among the secondary rectal data set was 3.50%; the
corresponding misclassification rate among the associated
withheld pairs was 3.16%. Confusion matrices associated with
the random forest and logistic models for both the colon and
rectal data sets are presented in Table 3. Summary information regarding the PCA and logistic modeling results is found in
Table 4. Additionally, among the secondary data sets we
tested for differences in PCA score profiles across sex, tumor
site, and tumor stage categories, considering tumor observations separately from non-tumor observations. We did not
observe evidence of interactions between the PCA scores and
these categorical variables; a summary of these results is
included in the Supplementary Table S2.
Regarding the miRNAs identified as most important in
distinguishing between tissue type among the colon and rectal
data sets, Table 5 contains bioinformatics analysis results
including the number of target mRNAs identified, and
associated enriched biological processes and pathways.
Fairly conservative identification methods were used (i.e.,
verified mRNA targets only combined with false discovery rate
o0.05); important miRNAs for which target mRNAs were not
identified were excluded from presentation in Table 5. Of the
miRNAs associated with colon tissue only, hsa-miR-663a was
associated with four enriched biological processes, and hsamiR-92-5p was associated with nine enriched biological
processes and eight enriched KEGG pathways. Three
miRNAs associated with both colon and rectal tissue targeted
mRNAs enriched for multiple processes and KEGG pathways.
Hsa-miR-17-5p was associated with six enriched biological
processes and seven enriched KEGG pathways, and hsamiR-20a-5p and hsa-miR-21-5p were both associated with the

same nine enriched processes and eight enriched KEGG
pathways. Hsa-miR-378a-3p was identified among both the
colon and rectal data sets and was associated with just one
significantly enriched KEGG pathway, “pathways in cancer”,
whereas hsa-miR-145-5p, also identified among both data
sets, targeted genes that were not significantly enriched for
any pathways but were enriched for five biological processes.
None of the miRNAs associated with rectal tissue only had any
targeted genes enriched for either biological processes or
KEGG pathways. Of the gene (mRNA) targets identified in
association with the important miRNAs, 26 contributed to the
identification of significantly enriched KEGG pathways, five of
which were targeted by multiple miRNAs. Regarding the
enriched biological processes, 100 target genes contributed to
the identification of these processes, 11 of which were
targeted by multiple miRNAs identified as important. The
genes associated with KEGG pathways and biological
processes as well as the miRNAs for which they are verified
targets are included in the Supplementary Table S3.
Table 6 contains results comparing the Agilent platform
measurements with those from qPCR among several miRNA
identified as important. qPCR miRNA expression was
measured for hsa-miR-663b, hsa-miR-17-5p, hsa-miR-20a5p, hsa-miR-93-5p, hsa-miR-21-5p, hsa-miR-92a-3p, hsamiR-3651, hsa-miR-4506, hsa-miR-4538, hsa-miR-215, and
hsa-miR-1183. All fold changes between carcinoma tissue
and normal colonic mucosa followed the same pattern among
qPCR measurements and Agilent measurements, i.e., each
miRNA with a fold change of o1 when measured by the
Agilent platform also had a fold change of o1 when measured
via qPCR and vice versa for miRNA with fold changes 41.
Additionally, most of the miRNA expressions displayed a high
level of correlation between Agilent and qPCR measurements;
75% of the correlations computed were 40.5. We believe this
demonstrates a high level of agreement between the Agilent
platform expression measurements and those from qPCR and
Clinical and Translational Gastroenterology
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Figure 2 Scatterplots of microRNA (miRNA) expression values among primary
colon and rectal data sets. Axes measure log 2(1+expression value). Observations
were randomly ordered to avoid any data-order artifacts in this visualization.

provides a degree of validation with regard to the platform
used in generating our data, the Agilent platform.
DISCUSSION
The miRNAs identified appear viable for distinguishing
between carcinoma and normal colonic mucosa at the
molecular level. Estimated misclassification rates were low
and we identified 16 miRNAs of particular importance in
discriminating between colon carcinoma tissue and normal
mucosa; similarly, 17 miRNAs were identified as particularly
important with regard to rectal carcinoma classification.
Clinical and Translational Gastroenterology

Among independent observations, logistic modeling coupled
with PCA verified findings via parsimonious predictive models
of carcinoma vs. normal mucosa using only the miRNAs
identified via random forest analysis and similar classification
accuracy was observed. This study helps describe the
landscape of miRNAs as they relate to CRC. It is hoped that
the ability to narrow focus to key molecular differences
between carcinoma and adjacent normal mucosa will aid
future clinical research, from screening tools to targeted
therapeutic modalities.
Bioinformatics tools identified several miRNA targets,
enriched biological processes, and pathways associated with
miRNAs identified as important among the colon and rectal
data sets. One of the most common threads in the pathways
identified with these miRNAs was angiogenesis. This suggests that these miRNAs have the potential to contribute to
the metastatic potential of tumors. Additionally, several of the
miRNAs identified as important have been identified in the
previous research. Hsa-miR-21 identified in this study as
important for both colon and rectal study has been studied
extensively with colon cancer.9,30–34 Hsa-miR-663b was
shown to be upregulated in bladder cancer plasma, as such
has been proposed as a biomarker in clinical bladder cancer
detection,35 and it has also been seen to be involved in cell
proliferation, migration, apoptosis, and regulation of MAP/ERK
(mitogen-activated protein/extracellular signal-regulated
kinase) signaling in a study of CRC cell lines.36 Both hsamiR-21-5p and hsa-miR-17-5p were seen to be significantly
dysregulated in a CRC study by Kara et al.37 Additionally,
higher hsa-miR-17-5p expression was correlated with drug
resistance and metastasis in CRC patients in a 2014 study by
Fang et al.38 MiRNA hsa-miR-4323 was correlated with tumor
relapse in patients with small-cell esophageal carcinoma.39
Other miRNAs identified as important, which have
been previously reported as associated with CRC, include
miR-20a,31,32,40 miR-92a,41 miR-192-5p,42 miR-145,40,43–45
miR-93,46 and miR-150.47
Previous analysis of our data indicated that a large
percentage of miRNAs exhibit dysregulation between carcinoma tissue and normal mucosa.10 To consider if we could
achieve similar misclassification rates with alternative subsets
of miRNAs, we removed those identified as important from
consideration and repeated our analysis. Obtaining new
subsets of important miRNAs for colon and rectal in the same
manner as before, we again removed these secondary
findings from consideration and repeated the analysis a third
time. Considering the colon data set, the second round of
analysis identified 27 miRNAs as most important and resulted
in an OOB estimated error rate for the new random forest
model among the primary data set of 7.78% and a leave-oneout estimated error rate for the newly fitted logistic model of
10.50% among the secondary data set. The third round of
analysis using the colon data set identified 48 miRNAs as
most important, whereas the OOB error estimate among the
primary data set using random forest modeling was 11.48%
and the leave-one-out estimate associated with logistic
modeling in the secondary data set was 12.66%. Considering
the rectal data set, the second round of analysis identified 20
miRNAs as most important; the OOB error estimate associated with random forest modeling was 4.29%, whereas the
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Table 3 Confusion matrices associated with random forest and logistic classification models

Random forest model

Error
ratea

Colon data set
Primary data set
Actual

Logistic model

Error
ratea

Secondary data set
Normal
mucosa
Carcinoma

Predicted
Normal mucosa Carcinoma
384
29
19

Actual

561

Normal
mucosa
Carcinoma

Predicted
Normal mucosa
Carcinoma
83
7
6

104

4.83%
Pairs withheld from model fitting
Actual

Normal
mucosa
Carcinoma

6.50%
Pairs withheld from model fitting

Predicted
Normal mucosa Carcinoma
389
27
10

Actual

372

Normal
mucosa
Carcinoma

Predicted
Normal mucosa
Carcinoma
73
5
3

76

4.64%
Rectal data set
Primary data set
Actual

5.10%
Secondary data set

Normal
mucosa
Carcinoma

Predicted
Normal mucosa Carcinoma
213
6
8

Actual

333

Normal
mucosa
Carcinoma

Predicted
Normal mucosa
87

Carcinoma
3

4

106

2.50%
Pairs withheld from model fitting
Actual

Normal
mucosa
Carcinoma

3.50%
Pairs withheld from model fitting

Predicted
Normal mucosa Carcinoma
211
11
4

Actual

201

Normal
mucosa
Carcinoma

Predicted
Normal mucosa
69

Carcinoma
2

3

84

3.51%

3.16%

OOB, out-of-bag.
a
Error rates for primary data sets are OOB estimates; error rates for secondary data sets are leave-one-out estimates.

Table 4 Logistic models and related PCA results

Intercept

Logistic model
Est. coefficient
S.e.
P-value

1.19
0.46
0.01

Corresponding PCA resultsb
% of sample var.

Colon
Comp. 1a

Comp. 2

Comp. 3

− 1.40
0.27
o0.001

− 1.09
0.28
o0.001

− 1.95
0.48
o0.001

38.24

24.86

13.30

Included miRNA
Hsa-miR-663b
Hsa-miR-4539
Hsa-miR-17-5p
Hsa-miR-20a-5p
Hsa-miR-663a
Hsa-miR-4538
Hsa-miR-21-5p
Hsa-miR-215
Hsa-miR-4506
Hsa-miR-92a-3p
Hsa-miR-93-5p
Hsa-miR-192-5p
Hsa-miR-145-5p
Hsa-miR-3651
Hsa-miR-378a-3p
Hsa-miR-378i
—

Intercept

Loadings
− 0.08
0.26
− 0.38
− 0.37
0.04
0.26
− 0.33
− 0.08
− 0.20
− 0.33
− 0.36
− 0.10
− 0.02
− 0.33
0.17
0.17
—

− 0.07
0.25
0.09
0.10
0.01
0.26
0.14
0.42
− 0.22
0.13
0.11
0.42
0.26
0.11
0.41
0.39
—

Est. coefficient
S.e.
P-value
% of Sample var.

3.07
0.83
o0.001

Rectal
Comp. 1a

Comp. 3

− 2.90
0.54
o0.001

− 1.32
0.46
o0.01

0.95
0.43
0.03

8.67

6.56

44.66

Included miRNA
− 0.62
− 0.23
− 0.09
− 0.08
− 0.62
− 0.16
0.00
0.18
0.04
− 0.12
− 0.02
0.17
0.18
− 0.12
− 0.08
− 0.09
—

Hsa-miR-663b
Hsa-miR-17-5p
Hsa-miR-4323
Hsa-miR-20a-5p
Hsa-miR-378a-3p
Hsa-miR-93-5p
Hsa-miR-4539
Hsa-miR-378i
Hsa-miR-21-5p
Hsa-miR-92a-3p
Hsa-miR-145-5p
Hsa-miR-150-5p
Hsa-miR-3651
Hsa-miR-4749-3p
Hsa-miR-4506
Hsa-miR-424-3p
Hsa-miR-6073

Comp. 4

Loadings
− 0.23
− 0.31
0.24
− 0.30
0.20
− 0.30
0.28
0.19
− 0.26
− 0.29
0.10
0.15
− 0.26
0.25
− 0.24
− 0.24
0.15

− 0.36
− 0.08
− 0.40
− 0.08
− 0.12
− 0.04
− 0.30
− 0.12
0.12
− 0.12
0.29
0.21
− 0.15
− 0.30
0.27
− 0.22
0.42

− 0.30
0.07
0.30
0.10
− 0.39
− 0.01
− 0.01
− 0.39
0.35
0.13
0.07
− 0.14
0.09
0.31
− 0.39
−0.05
0.27

AIC, Akaike information criterion; miRNA, microRNA; PCA, principal component analysis.
a
The components listed are those included in the model; model selection was based on AIC statistics.
b
Loadings and % of sample variance refer to the component listed in the corresponding column.
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Table 5 miRNA contribution to enriched biological processes and pathwaysa

miRNA

No. of
targetsb

Rectal and colon tissue
Hsa-miR-17-5p

5

Hsa-miR-20a-5p

8

Hsa-miR-378a-3p
Hsa-miR-21-5p

1
289

Hsa-miR-92a-3p
Hsa-miR-145-5p

3
10

Hsa-miR-3651

24

Colon tissue only
Hsa-miR-663a

1

Hsa-miR-92-5p

346

Rectal tissue only
Hsa-miR-150-5p

Enriched biological processesc

Enriched pathwaysc

Phosphate metabolic process, angiogenesis, intracellular
signaling cascade, blood vessel and vasculature development, interphase of mitotic cell cycle, blood vessel
morphogenesis
Phosphate metabolic process, angiogenesis, intracellular
signaling cascade, blood vessel and vasculature development, positive regulation of angiogenesis, negative
regulation of cell differentiation, interphase of mitotic cell
cycle, blood vessel morphogenesis, positive regulation of
transcription from RNA polymerase II promoter

Melanoma, chronic myeloid leukemia, small-cell
lung cancer, glioma, prostate cancer, pathways
in cancer, p53 signaling pathway

Phosphate metabolic process, angiogenesis, intracellular
signaling cascade, blood vessel and vasculature development, positive regulation of angiogenesis, negative
regulation of cell differentiation, interphase of mitotic cell
cycle, blood vessel morphogenesis, positive regulation of
transcription from RNA polymerase II promoter

Melanoma, pancreatic cancer, chronic myeloid
leukemia, small-cell lung cancer, glioma, prostate cancer, pathways in cancer, p53 signaling
pathway
Pathways in cancer
Melanoma, pancreatic cancer, chronic myeloid
leukemia, small-cell lung cancer, glioma, prostate cancer, pathways in cancer, p53 signaling
pathway

Phosphate metabolic process, intracellular signaling
cascade, interphase of mitotic cell cycle, negative
regulation of cell differentiation, positive regulation of
transcription from RNA polymerase II promoter

Blood vessel and vasculature development, blood vessel
morphogenesis, positive regulation of transcription from
RNA polymerase II promoter
Phosphate metabolic process, angiogenesis, intracellular
signaling cascade, blood vessel and vasculature development, positive regulation of angiogenesis, negative
regulation of cell differentiation, interphase of mitotic cell
cycle, blood vessel morphogenesis, positive regulation of
transcription from RNA polymerase II promoter

Melanoma, pancreatic cancer, chronic myeloid
leukemia, small-cell lung cancer, glioma, prostate cancer, pathways in cancer

1

FDR, false discovery rate; miRNA, microRNA.
a
All enriched processes and pathways were identified using DAVID (https://david.ncifcrf.gov/home.jsp).
b
Targets are from TarBase, using filters “Homo sapiens”.
c
Processes and pathways selected using o0.05 FDR.

leave-one-out estimated error rate associated with the logistic
model was 4.68%. The third round of analysis considering
rectal observations identified 35 miRNAs as important and the
random forest model had an OOB error estimate of 6.25%,
whereas the leave-one-out estimated error associated with the
logistic model was 8.43%. That is, we found several disjoint
subsets of important miRNAs from which decent misclassification rates could be achieved. However, we found that as
miRNAs previously identified as important were removed from
consideration, model classification suffered and the differences in the importance rank between miRNAs ranked
highest and those ranked lower diminished. In general, several
subsets of miRNAs were capable of discriminating between
carcinoma tissue and normal mucosa based on expression;
however, as those miRNAs initially identified as most
important were discarded from analysis, a greater number of
miRNAs were required and lower model accuracy was
observed. The miRNAs identified for the colon and rectal data
sets during the secondary and tertiary analysis runs as well as
the associated confusion matrices are included in the online
Supplementary Tables S4–S7.
Clinical and Translational Gastroenterology

Our study has several strengths including a large sample size
that enabled us to reproduce findings using alternative models
and methods among observations independent of those
considered in the primary analysis. Additionally, qPCR allowed
us to validate data characteristics with an alternative expression
measurement platform for several miRNAs identified as
important. However, all of our analysis restricted attention to
frequently expressed miRNAs, and other less frequently
expressed miRNAs could also be important for subsets of the
population. Although we used an Agilent microarray platform
and validated data characteristics among several key miRNAs
using qPCR, other platforms and methods of assessment could
have produced additional and/or alternative results in terms of
which miRNA expressions are deemed important, as concordance between results from different expression measurement platforms can vary.48 We used normal mucosa adjacent to
the tumor. While this was the only option to obtain non-tumor
colonic tissue, it has been shown that adjacent tissue may also
have genetic alterations.49 However, we were able to identify
unique miRNA patterns between the normal colonic mucosa
and carcinoma tissue.
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Table 6 Agilent platform measurements compared with qPCR measurements

Fold changea

Important miRNA

Correlation between platforms

Agilent platform

qPCR

Normal obs.

Tumor obs.

Colon
Hsa-miR-663b
Hsa-miR-17-5p
Hsa-miR-20a-5p
Hsa-miR-4538
Hsa-miR-21-5p
Hsa-miR-215
Hsa-miR-4506
Hsa-miR-92a-3p
Hsa-miR-93-5p
Hsa-miR-3651

2.16
2.75
2.91
0.77
2.70
0.55
1.34
2.56
2.09
2.37

2.23
3.05
3.15
0.14
3.15
0.29
1.22
2.59
2.17
2.25

0.58
0.88
0.87
0.01
0.71
0.59
0.06
0.82
0.85
0.70

0.57
0.83
0.83
0.34
0.65
0.39
0.38
0.72
0.73
0.65

Rectal
Hsa-miR-663b
Hsa-miR-17-5p
Hsa-miR-20a-5p
Hsa-miR-93-5p
Hsa-miR-21-5p
Hsa-miR-92a-3p
Hsa-miR-3651
Hsa-miR-4506

2.09
3.13
3.34
2.25
3.09
2.33
2.24
1.46

2.78
4.22
4.45
2.79
4.07
2.85
2.56
1.11

-0.08
0.78
0.82
0.87
0.55
0.87
0.67
-0.14

0.39
0.91
0.93
0.70
0.95
0.76
0.80
0.07

qPCR, quantitative PCR.
a
Calculated as mean tumor/mean normal.

Results from this study are an important step to understanding the clinical relevance of miRNAs and their potential
use for screening, early detection, and therapeutic modalities.
In our previous work, we identified over 500 miRNAs that were
differentially expressed between carcinoma and normal
mucosa.10 However, given the number of dysregulated
miRNAs, our aim in this study was to determine if a smaller
subset of miRNAs could be identified that could then be
explored for their clinical relevance. Based on the analysis of
all known miRNAs, we identified a small group that could
accurately distinguish between normal colonic mucosa and
carcinoma tissue. This group of miRNAs represents a group of
miRNAs that when considered together helps to define
colorectal carcinoma. Although some of these miRNAs have
been studied extensively, we know little about the pathways
and functions of other miRNAs in this group. Having a welldefined subset of miRNAs associated with colorectal carcinoma tissue allows for more focused studies regarding
specific gene targets and subsequent pathways. While we
examined KEGG pathways to help identify relevant pathways
for these miRNAs, there are limitations in the current knowledgebase. Some of the miRNAs that have been studied
extensively, such as miR21, have been linked to many genes
and disease pathways. It is unclear which of these genes and
pathways are most relevant for CRC. Other miRNAs that have
not been studied extensively have been linked only to a few
genes and a few pathways. Having a group of miRNAs
specifically associated with CRC will guide research to better
defined important pathways that will hopefully provide the
basis for developing CRC-specific therapeutics.
Using a set of miRNAs to delineate a CRC-specific pathway
may be especially important as new screening methods
emerge, including the use of liquid biopsies. Nonspecificity
of few well-studied miRNAs presents a problem for such

screening test, whereas a set of miRNAs specific to CRC
could prove to be useful for that purpose. The metastatic
potential associated with this set of miRNAs is currently not
known. However, further evaluation of the ability of this set of
miRNAs to predict adenomas that have a greater potential for
carcinoma development could enhance our ability to identify
individuals who may require different screening guidelines.
The clinical relevance of this subset of miRNAs, although
promising, has yet to be fully understood. This study helps
describe the landscape of miRNAs as they relate to CRC.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ MiRNA are noncoding RNA molecules that alter gene
activity.
✓ Many miRNAs are dysregulated in CRC tissue.

WHAT IS NEW HERE
✓ 16 miRNAs for colon and 17 miRNAs for rectal carcinoma
differentiated between carcinoma and normal mucosa.
✓ 12 miRNAs were important discriminators of carcinoma and
normal mucosa for colon and rectal carcinoma.
✓ MiRNA expression levels were validated with qPCR.
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